Related Experiment Video

Updated: Mar 31, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

18.9K

Effect of plasma NOx values on cardiac function in obese hypertensive and normotensive pediatric patients

Meltem Akcaboy1, Serdar Kula2, Tayfun Göktas3

  • 1Department of Pediatric Nephrology, Gazi University School of Medicine, Konya yolu, 06500, Besevler, Ankara, Turkey. meltemileri@yahoo.com.

Pediatric Nephrology (Berlin, Germany)
|October 21, 2015
PubMed

Insights

Obese children with hypertension have lower plasma nitric oxide (NOx) levels, which are linked to heart muscle thickening. These findings highlight NOx

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Research
  • Obesity and Hypertension

Background:

  • Hypertension is a significant comorbidity in obese children, increasing cardiovascular disease risk.
  • Obesity-associated hypertension in pediatrics requires further investigation into its underlying mechanisms.
  • Understanding cardiac implications in pediatric obesity is crucial for long-term health outcomes.

Purpose of the Study:

  • To assess cardiac function in obese hypertensive (OHT) versus obese normotensive (ONT) pediatric patients.
  • To determine the impact of plasma nitric oxide (NOx) on cardiac function in these groups.
  • To elucidate the role of plasma NOx in the development of hypertension in obese children.

Main Methods:

  • Echocardiography and ambulatory blood pressure monitoring were used to evaluate cardiac function and hypertension.
  • Plasma nitric oxide (NOx) and biochemical markers were analyzed in 62 pediatric patients (13-18 years) and 21 controls.
  • Patients were categorized into obese hypertensive (OHT) and obese normotensive (ONT) groups for comparative analysis.

Main Results:

  • Obese hypertensive (OHT) patients exhibited significantly lower plasma NOx levels compared to obese normotensive (ONT) and control groups (p < 0.001).
  • Plasma NOx levels showed a negative correlation with left ventricular mass index (p < 0.05).
  • Both OHT and ONT groups presented with concentric hypertrophy, indicating cardiac structural changes.

Conclusions:

  • Plasma nitric oxide (NOx) is a critical factor in the pathogenesis of obesity-induced hypertension in pediatric patients.
  • Concentric left ventricular hypertrophy was observed in both obese hypertensive and normotensive children, suggesting structural cardiac remodeling.
  • Reduced plasma NOx may contribute to cardiac structural alterations in obese youth, irrespective of hypertensive status.
Abstract

Keywords:
ChildrenEchocardiographyHypertensionObesePlasma NOx

More Related Videos

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

964
Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS08:12

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

Published on: November 26, 2018

10.8K

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
341
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
381
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
464
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
283
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K